Life Sciences Blog

The principles of HTA in Ukraine: A presentation at the Ukrainian Pharmaceutical Forum




Today, I had the privilege of making a presentation about health technology assessment (HTA) to an audience of pharmaceutical industry professionals and other stakeholders in Ukraine as part of the Ukrainian Pharmaceutical Forum taking place in Kiev. I hope my comments about what HTA is, its costs and benefits, and the international experience with HTA are useful as the country takes its first steps towards the introduction of reimbursement for pharmaceuticals.

You can view my presentation slides here.

In addition, we will be presenting research at ISPOR in Dublin on IRP in the Ukraine. If you are attending ISPOR please stop by booth 117 to talk to us about our research on IRP, the Ukraine health system, and HTA. If you are not attending, you can search for our abstract on the ISPOR online database to see the poster. The title of the poster is "A Review of the Application of International Reference Pricing in Ukraine’s Pilot Hypertension Reimbursement Scheme".

About The Author

Milena Izmirlieva is head of the Life Sciences research team at IHS Markit. Her areas of expertise include market access, pricing and reimbursement, HTA, generics and biosimilars, corporate strategies, and pharma promotion and advertising.